+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dravet Syndrome Market - Global Forecast 2025-2030- Product Image
Dravet Syndrome Market - Global Forecast 2025-2030- Product Image
Sale

Dravet Syndrome Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6084060
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Dravet Syndrome Market is experiencing notable transformation, driven by complex clinical needs, emerging therapies, and shifting regulatory frameworks. Senior decision-makers require clear, actionable analysis to guide investment, R&D, and go-to-market strategies in this rapidly evolving therapeutics sector.

Market Snapshot: Dravet Syndrome Market Size & Growth Outlook

The Dravet Syndrome Market grew from USD 734.04 million in 2024 to USD 800.08 million in 2025. It is expected to continue growing at a CAGR of 8.75%, reaching USD 1.21 billion by 2030. Robust expansion is underpinned by increased demand for novel therapies, ongoing unmet patient needs, and regional investments. As regulatory pathways adapt and precision-medicine solutions become more accessible, the addressable patient population is poised for further growth. Industry leaders are engaging in strategic partnerships, expanding treatment portfolios, and actively exploring both traditional and digital care models to optimize delivery.

Scope & Segmentation

This research covers key segments and regions critical for informed planning and market entry. The report provides detailed analysis across the following dimensions:

  • Drug Classes: Cannabinoids (CBD, THC), GABA modulators (clobazam, diazepam, stiripentol), and sodium channel blockers (topiramate, valproate).
  • End Users: Home care settings, hospital-based care, specialty epilepsy centers.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, specialty pharmacies, online pharmacies.
  • Routes of Administration: Injectable formulations, nasal sprays, oral tablets, oromucosal solutions, transdermal patches.
  • Patient Age Groups: Infants, children, adolescents, adults.
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (e.g., United Kingdom, Germany, South Africa, Saudi Arabia), Asia-Pacific (e.g., China, India, Japan, Australia, South Korea, Singapore).
  • Key Companies: Jazz Pharmaceuticals plc, UCB SA, Marinus Pharmaceuticals, Inc., Stoke Therapeutics, Inc., Zogenix, Inc., Biogen Inc., Ionis Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., Ovid Therapeutics, Inc., Zynerba Pharmaceuticals, Inc.

Market segmentation enables stakeholders to target product development and commercial activities efficiently, with special attention to evolving regulatory environments and shifting patient demographics across global regions.

Key Takeaways for Senior Decision Makers

  • Breakthroughs in genetic testing and precision medicine are reshaping therapeutic standards and fostering the development of targeted interventions.
  • Caregiver advocacy and patient engagement are influencing clinical trial designs and accelerating access to emerging therapies.
  • Supply chain resilience is a growing priority as organizations respond to both regulatory changes and external market pressures.
  • Regional investment trends reveal distinct patterns: established reimbursement frameworks in the Americas, harmonizing assessments in Europe and the Middle East, and capacity-building initiatives in Asia-Pacific.
  • Collaborative frameworks between academia, industry, and advocacy organizations support shared data repositories and foster more adaptive studies.
  • Intellectual property management, including cross-licensing and patent pooling, is facilitating access to platform technologies and expanding therapeutic options.

Tariff Impact: U.S. Tariff Changes and Industry Response

The implementation of new U.S. tariffs in 2025 has led manufacturers and healthcare organizations to reassess sourcing and procurement strategies. Increased duties on pharmaceutical ingredients are impacting overall costs, encouraging long-term supplier agreements, and driving interest in domestic production and diversified supply chains. Hospitals and specialty centers are adjusting acquisition strategies and reevaluating support programs, balancing financial pressures with the need to ensure patient access to critical orphan drugs. Strategic collaborations and co-investment in tariff impact analyses guide proactive resource planning and maintain innovation pipelines.

Methodology & Data Sources

This analysis incorporates primary interviews with clinicians, payers, and patient advocates to capture firsthand market perspectives. Rigorous secondary research includes peer-reviewed literature, regulatory documents, and tracking of clinical trial and reimbursement activity. Advanced validation techniques, such as triangulation and custom database analysis, underpin the report’s reliability and actionable findings.

Why This Report Matters

  • Informs strategic investment and R&D by clarifying the most relevant growth areas across geographies, technologies, and patient populations.
  • Supports market-access planning and operational efficiency through detailed segmentation and up-to-date regulatory insights.
  • Enables proactive risk management by detailing key supply chain, tariff, and policy developments in Dravet Syndrome therapeutics.

Conclusion

The Dravet Syndrome Market is evolving with scientific, commercial, and regulatory advancements. This report delivers critical intelligence for leaders seeking to optimize patient outcomes and drive innovation. Strategic alignment across R&D, access, and operational disciplines is essential for success in this complex landscape.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of gene therapy pipelines targeting SCN1A mutations in Dravet syndrome patients
5.2. Increasing adoption of cannabidiol-based formulations for adjunctive seizure management in Dravet syndrome
5.3. Rising investments in precision medicine initiatives for pediatric epileptic encephalopathies treatment
5.4. Growing integration of real-world evidence to assess long-term treatment outcomes in Dravet syndrome
5.5. Emergence of novel antisense oligonucleotides tailored to modulate defective sodium channel gene expression
5.6. Development of at-home seizure monitoring devices leveraging AI for real-time intervention in Dravet syndrome
5.7. Collaborations between pharmaceutical and biotech firms to accelerate clinical trials in rare epilepsy disorders
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dravet Syndrome Market, by Drug Class
8.1. Introduction
8.2. Cannabinoids
8.2.1. Cbd
8.2.2. Thc
8.3. Gaba Modulators
8.3.1. Clobazam
8.3.2. Diazepam
8.3.3. Stiripentol
8.4. Sodium Channel Blockers
8.4.1. Topiramate
8.4.2. Valproate
9. Dravet Syndrome Market, by End User
9.1. Introduction
9.2. Home Care
9.3. Hospital
9.4. Specialty Epilepsy Centers
10. Dravet Syndrome Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.5. Specialty Pharmacies
11. Dravet Syndrome Market, by Route Of Administration
11.1. Introduction
11.2. Injectable
11.3. Nasal
11.4. Oral
11.5. Oromucosal
11.6. Transdermal
12. Dravet Syndrome Market, by Patient Age Group
12.1. Introduction
12.2. Adolescents
12.3. Adults
12.4. Children
12.5. Infants
13. Americas Dravet Syndrome Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Dravet Syndrome Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Dravet Syndrome Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Jazz Pharmaceuticals plc
16.3.2. UCB SA
16.3.3. Marinus Pharmaceuticals, Inc.
16.3.4. Stoke Therapeutics, Inc.
16.3.5. Zogenix, Inc.
16.3.6. Biogen Inc.
16.3.7. Ionis Pharmaceuticals, Inc.
16.3.8. Xenon Pharmaceuticals Inc.
16.3.9. Ovid Therapeutics, Inc.
16.3.10. Zynerba Pharmaceuticals, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DRAVET SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. DRAVET SYNDROME MARKET: RESEARCHAI
FIGURE 26. DRAVET SYNDROME MARKET: RESEARCHSTATISTICS
FIGURE 27. DRAVET SYNDROME MARKET: RESEARCHCONTACTS
FIGURE 28. DRAVET SYNDROME MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DRAVET SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CBD, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY THC, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAZEPAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TOPIRAMATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY EPILEPSY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DRAVET SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DRAVET SYNDROME MARKET SIZE, BY NASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OROMUCOSAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CHILDREN, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL DRAVET SYNDROME MARKET SIZE, BY INFANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 113. CANADA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. CANADA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. CANADA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 116. CANADA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 117. CANADA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 118. CANADA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 119. CANADA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 120. CANADA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 121. CANADA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. CANADA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. CANADA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. CANADA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. CANADA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. CANADA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. CANADA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 128. CANADA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 129. MEXICO DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 132. MEXICO DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 133. MEXICO DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 134. MEXICO DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. MEXICO DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. MEXICO DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. MEXICO DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. MEXICO DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. MEXICO DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. MEXICO DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 144. MEXICO DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. GERMANY DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 214. GERMANY DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 215. GERMANY DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 216. GERMANY DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 217. GERMANY DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 218. GERMANY DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 219. GERMANY DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. GERMANY DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. GERMANY DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. GERMANY DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. GERMANY DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. GERMANY DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. GERMANY DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 226. GERMANY DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 227. FRANCE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 230. FRANCE DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 231. FRANCE DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 232. FRANCE DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 233. FRANCE DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 234. FRANCE DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 235. FRANCE DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. FRANCE DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. FRANCE DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. FRANCE DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. FRANCE DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. FRANCE DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. FRANCE DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 242. FRANCE DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 259. ITALY DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 260. ITALY DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 261. ITALY DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 262. ITALY DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 263. ITALY DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 264. ITALY DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 265. ITALY DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 266. ITALY DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 267. ITALY DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. ITALY DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. ITALY DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. ITALY DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. ITALY DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. ITALY DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. ITALY DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 274. ITALY DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 275. SPAIN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 276. SPAIN DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 277. SPAIN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 278. SPAIN DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 279. SPAIN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 280. SPAIN DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 281. SPAIN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 282. SPAIN DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 283. SPAIN DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. SPAIN DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. SPAIN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. SPAIN DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. SPAIN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. SPAIN DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. SPAIN DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 290. SPAIN DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 320. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 322. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 328. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 330. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SODIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 331. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 332. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 333. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 334. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 335. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 336. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 337. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 338. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 339. DENMARK DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 340. DENMARK DRAVET SYNDROME MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 341. DENMARK DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2018-2024 (USD MILLION)
TABLE 342. DENMARK DRAVET SYNDROME MARKET SIZE, BY CANNABINOIDS, 2025-2030 (USD MILLION)
TABLE 343. DENMARK DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2018-2024 (USD MILLION)
TABLE 344. DENMARK DRAVET SYNDROME MARKET SIZE, BY GABA MODULATORS, 2025-2030 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Dravet Syndrome market report include:
  • Jazz Pharmaceuticals plc
  • UCB SA
  • Marinus Pharmaceuticals, Inc.
  • Stoke Therapeutics, Inc.
  • Zogenix, Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • Xenon Pharmaceuticals Inc.
  • Ovid Therapeutics, Inc.
  • Zynerba Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 800.08 Million
Forecasted Market Value ( USD ) by 2030 $ 1210 Million
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dravet Syndrome (DS) Epidemiology Forecast 2025-2034 - Product Image

Dravet Syndrome (DS) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Dravet Syndrome - Global Strategic Business Report - Product Image

Dravet Syndrome - Global Strategic Business Report

  • Report
  • 485 Pages
  • Global
From
Dravet Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Dravet Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 77 Pages
  • Global
From
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2024 - Product Image

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 134 Pages
  • Global
From

About the Market

Dravet Syndrome is a rare, severe form of epilepsy that begins in infancy and is characterized by frequent, prolonged seizures. Treatment of Dravet Syndrome typically involves a combination of antiepileptic drugs, dietary therapies, and other therapies. Within the context of Central Nervous System Drugs, the Dravet Syndrome Drug market is a specialized segment of the larger epilepsy drug market. It is composed of drugs that are specifically designed to treat Dravet Syndrome, as well as drugs that are used off-label to treat the condition. The Dravet Syndrome Drug market is composed of both generic and branded drugs. Some of the companies in the market include GW Pharmaceuticals, Zogenix, Eisai, and UCB. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.